

## **Baicalein Induces p27<sup>kip</sup> Degradation Through PI3K-Akt Pathway in Oral Cancer Cells**

\*PinXiuan Huang<sup>1</sup> and YaHsin Cheng<sup>2</sup>

<sup>2</sup>Department of Physiology, School of Medicine, China Medical University, Taiwan, ROC

<sup>1</sup>Department of Medical Laboratory Science and Biotechnology, China Medical University, Taiwan, ROC

Baicalein is a flavonoid known to have anti-inflammatory and anti-cancer effects. In a previous study, we reported that baicalein induced hypophosphorylation of Rb, causing G1 phase arrest through activation of AhR and down-regulation of cyclin D1 and CDK4 in oral cancer cells (HSC-3). In this study, we found that in baicalein-treated HSC-3, although Rb was hypophosphorylated, the expression of p27<sup>kip</sup>, a CDK inhibitor was decreased to a level less than that in cells without baicalein treatment, which suggests that the reduction of P27<sup>kip</sup> may not be one of the causes of the hypophosphorylation of Rb. Using Western Blot to investigate how baicalein down-regulates p27<sup>kip</sup> expression, we found that baicalein treatment induced an increase in the amount of phosphorylated Akt (pAkt) at 12 and 24h. Such an increase caused an immediate corresponding reduction of the p27<sup>kip</sup>. To confirm the association of Akt pathway with the p27<sup>kip</sup> degradation, we pretreated the cells with an Akt inhibitor, MK2206, and demonstrated that the blocking of phosphorylation of Akt reversed the expression of p27<sup>kip</sup> and reduced phosphorylated p27<sup>kip</sup> (Thr187) at 12 and 24h in the baicalein-treated cells. Knowing that PI3K is an upstream signal protein of Akt, we further pretreated the cells with a PI3K inhibitor, LY294002, and demonstrated that the level of pAkt was decreased, whereas the reduction of p27<sup>kip</sup> was slightly reversed and phosphorylated p27<sup>kip</sup> (Thr187) was decreased in the baicalein-treated cells. This indicates that, in baicalein-treated HSC-3, activation of PI3K induces phosphorylation of Akt and a subsequent signaling, which in turn increases phosphorylation of p27<sup>kip</sup> (Thr187), and thereby increases the degradation of p27<sup>kip</sup>. Our data revealed that baicalein down-regulates p27<sup>kip</sup> through the PI3K-Akt pathway in oral cancer cells. Since down-regulation of p27<sup>kip</sup> is reportedly correlated with oral squamous cell carcinoma (OSCC) and its metastasis, with a poor prognosis for patients, our results suggest that baicalein's effect on the reduction of p27<sup>kip</sup> in the oral cancer cells may have a negative effect by inducing tumor cell migration and invasion-- thus countering baicalein's positive effect of inhibiting tumor growth (via reduction of cyclinD1 and CDK4). Further studies are urgently needed to determine the exact impact of down-regulation of p27<sup>kip</sup> on baicalein-treated cancer cells.